The pharma company said the drug combined with eltrombopag demonstrated a significant improvement in time to treatment ...

Ianalumab is a fully human monoclonal antibody designed to deplete B cells via antibody-dependent cellular toxicity and inhibit BAFF-R-mediated signals of B cell function and survival.

Novartis' ianalumab plus eltrombopag significantly extended treatment response and improved platelet counts in a Phase 3 ...

Novartis’ ianalumab has shown success in the third trial readout in two days, after it met both its endpoints in a Phase III ...

A day after posting a pair of phase 3 wins for the tricky indication of Sjögren's syndrome, the Swiss pharma has unveiled a ...

Novartis is hoping to gain approval for its Sjögren’s disease drug after it met the endpoints in two Phase III trials. The ...

The drug, ianalumab, met its objectives in two Phase 3 studies in Sjögren’s syndrome, boosting the outlook of a ...

A mere 24 hours after Novartis' ianalumab hit the mark in two phase 3 trials in Sjogren's syndrome, the drug has delivered ...

In the Phase III VAYHIT2 trial, ianalumab combined with eltrombopag significantly prolonged time to treatment failure and ...

Novartis may have abandoned one Sjögren's syndrome asset this year, but it looks like the drugmaker has a winner on its hands ...

Ianalumab prolonged the duration of safe platelet levels during and after treatment in patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids1,2 Patients treated ...

Novartis today announced positive top-line results from its Phase III trials evaluating ianalumab (VAY736) in adults with ...